Enhanced System for Reducing HPV Incidence and Prevalence

The inventive concept provides an advanced system for reducing the incidence and prevalence of human papillomavirus (HPV) types 16 and 18 in women, offering improved protection against sexually transmitted infections and enhanced local immunity.

The original patent method for reducing HPV incidence and prevalence had limitations, including fixed surface area of the uterine cervical device, lack of real-time monitoring, and limited adaptability to individual cervical microbiomes. The new inventive concept addresses these limitations by introducing dynamically adjustable surface area, real-time monitoring, and personalized recommendations for maintaining a healthy microbiome.

The system comprises a uterine cervical device with a dynamically adjustable surface area between approximately 418 mm2 to approximately 524 mm2, a control unit for adjusting the surface area based on the user's cervical microbiome, and a data analytics module for tracking the user's microbiome profile and providing personalized recommendations. The device features a copper filament layer with a spiral coil configuration and a sensor for detecting changes in the cervical microbiome. The system can be used to apply a therapeutic dose of a copper-based antimicrobial agent to the uterine cervix, monitor the local immune response, and adjust the dosage and duration of treatment.

The new claims introduce the concept of dynamically adjustable surface area, real-time monitoring, and personalized recommendations, which are not present in the original patent. The combination of these features provides a novel and non-obvious solution for reducing HPV incidence and prevalence.

Alternative embodiments may include varying the material composition of the uterine cervical device, incorporating additional sensors for monitoring other health metrics, or integrating the system with existing healthcare infrastructure. Variations may include adapting the system for use in different patient populations or developing miniaturized versions for increased convenience.

The enhanced system has significant commercial potential in the healthcare industry, particularly in the areas of women's health, infectious disease prevention, and personalized medicine. The target market includes healthcare providers, pharmaceutical companies, and medical device manufacturers seeking to develop innovative solutions for reducing HPV incidence and prevalence.